These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8993572)

  • 21. Effect of citrate and aminotriazole on matrical plates induced in hepatic microbodies.
    Gotoh M; Griffin C; Hruban Z
    Virchows Arch B Cell Pathol; 1975; 17(4):279-94. PubMed ID: 166481
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clofibrate treatment in pigs: effects on parameters critical with respect to peroxisome proliferator-induced hepatocarcinogenesis in rodents.
    Luci S; Giemsa B; Hause G; Kluge H; Eder K
    BMC Pharmacol; 2007 Apr; 7():6. PubMed ID: 17437637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new multifunctional hydroxytyrosol-clofibrate with hypolipidemic, antioxidant, and hepatoprotective effects.
    Xie YD; Chen ZZ; Shao LH; Wang QT; Li N; Lu WF; Xu YH; Gao YQ; Guo LY; Liu HL; Li YP; Yang GD; Bian XL
    Bioorg Med Chem Lett; 2018 Oct; 28(18):3119-3122. PubMed ID: 30119959
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatic peroxisome proliferators induce morphologic transformation of Syrian hamster embryo cells, but not peroxisomal beta oxidation.
    Sanner T; Mikalsen SO; Rivedal E
    Prog Clin Biol Res; 1991; 369():77-89. PubMed ID: 1946545
    [No Abstract]   [Full Text] [Related]  

  • 25. Nonradioactive in situ hybridization for detection of mRNAs of peroxisomal enzymes in rat liver.
    Schad A; Fahimi HD; Völkl A; Baumgart E
    Ann N Y Acad Sci; 1996 Dec; 804():736-8. PubMed ID: 8993609
    [No Abstract]   [Full Text] [Related]  

  • 26. The effects of clofibrate and 3-amino-1,2,4-triazole on liver catalase and lipid metabolism in mice.
    Jones GL; Neill AR
    Biochim Biophys Acta; 1982 Aug; 712(2):420-6. PubMed ID: 7126616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of hypolipidemic drugs on hepatic CoA.
    Halvorsen O
    Biochem Pharmacol; 1983 Mar; 32(6):1126-8. PubMed ID: 6838659
    [No Abstract]   [Full Text] [Related]  

  • 28. Involvement of calmodulin- and protein kinase C-related mechanism in an induction process of peroxisomal fatty acid oxidation-related enzymes by hypolipidemic peroxisome proliferators.
    Watanabe T; Okawa S; Itoga H; Imanaka T; Suga T
    Biochim Biophys Acta; 1992 Apr; 1135(1):84-90. PubMed ID: 1591274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of three hypolipidemic drugs on catalase activity and peroxisomal and mitochondrial palmitate oxidation in rat cardiac and skeletal muscle.
    MacDonald RS; Swan PB
    Biochim Biophys Acta; 1986 Feb; 880(2-3):153-60. PubMed ID: 3942787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Different regulation of hepatic peroxisomal beta-oxidation activity in rats treated with clofibrate and partially hydrogenated marine oil.
    Horie S; Suga T
    Biochem Biophys Res Commun; 1990 Jan; 166(2):780-6. PubMed ID: 2302239
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Studies on hypolipidemic agents. III. Comparison of the hypolipidemic properties of 5-tridecylpyrazole-3-carboxylic acid and clofibrate.
    Seki K; Fukuda M; Isegawa J; Ohki M
    Chem Pharm Bull (Tokyo); 1984 Oct; 32(10):4103-9. PubMed ID: 6529804
    [No Abstract]   [Full Text] [Related]  

  • 32. The short- and long-term effects of bezafibrate in the rat.
    Fahimi HD; Reinicke A; Sujatta M; Yokota S; Ozel M; Hartig F; Stegmeier K
    Ann N Y Acad Sci; 1982; 386():111-35. PubMed ID: 6953842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peroxisome proliferators: species differences in response of primary hepatocyte cultures.
    Elcombe CR; Bell DR; Elias E; Hasmall SC; Plant NJ
    Ann N Y Acad Sci; 1996 Dec; 804():628-35. PubMed ID: 8993577
    [No Abstract]   [Full Text] [Related]  

  • 34. Targeted disruption of the peroxisome proliferator-activated receptor alpha gene, PPAR alpha.
    Lee SS; Gonzalez FJ
    Ann N Y Acad Sci; 1996 Dec; 804():524-9. PubMed ID: 8993570
    [No Abstract]   [Full Text] [Related]  

  • 35. Hepatic peroxisome proliferation: induction by BR-931, a hypolipidemic analog of WY-14,643.
    Reddy JK; Azarnoff DL; Sirtori CR
    Arch Int Pharmacodyn Ther; 1978 Jul; 234(1):4-14. PubMed ID: 708142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pretreatment with peroxisome proliferators protects mice against some but not all hepatotoxins.
    Nicholls-Grzemski FA; Burcham PC; Calder IC; Priestly BG
    Ann N Y Acad Sci; 1996 Dec; 804():742-4. PubMed ID: 8993611
    [No Abstract]   [Full Text] [Related]  

  • 37. The effect of non-genotoxic carcinogens, phenobarbital and clofibrate, on the relationship between reactive oxygen species, antioxidant enzyme expression and apoptosis.
    Díez-Fernández C; Sanz N; Alvarez AM; Wolf A; Cascales M
    Carcinogenesis; 1998 Oct; 19(10):1715-22. PubMed ID: 9806150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonradioactive in situ hybridization for detection of mRNAs encoding for peroxisomal proteins: heterogeneous hepatic lobular distribution after treatment with a single dose of bezafibrate.
    Schad A; Fahimi HD; Völkl A; Baumgart E
    J Histochem Cytochem; 1996 Aug; 44(8):825-34. PubMed ID: 8756755
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Competition studies of bovine liver catalase, synthetic peptides and artificial conjugates for luciferase import in a semipermeabilized cell system.
    Khemani VS; Nagaraj R
    Ann N Y Acad Sci; 1996 Dec; 804():701-5. PubMed ID: 8993599
    [No Abstract]   [Full Text] [Related]  

  • 40. Differential proto-oncogene mRNA induction from rats treated with peroxisome proliferators.
    Cherkaoui Malki M; Lone YC; Corral-Debrinski M; Latruffe N
    Biochem Biophys Res Commun; 1990 Dec; 173(3):855-61. PubMed ID: 2268348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.